Stephen Hanauer to Drug Monitoring
This is a "connection" page, showing publications Stephen Hanauer has written about Drug Monitoring.
Connection Strength
1.349
-
Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
Score: 0.630
-
Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
Score: 0.143
-
Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607.
Score: 0.136
-
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
Score: 0.134
-
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
Score: 0.123
-
Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2.
Score: 0.105
-
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
Score: 0.043
-
Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997 Sep; 92(9):1424-8.
Score: 0.035